Boehringer releases positive Phase I data of idarucizumab in renally impaired patients
A total of 46 male and female volunteers ranging from 45 to 80 years of age were included in the randomized, double-blind, placebo-controlled cross-over trial. The company said
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.